Wells Fargo & Company Silverback Therapeutics, Inc. Transaction History

Wells Fargo & Company

  • $407 Billion
  • Q2 2024

A detailed history of Wells Fargo & Company transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 15,756 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,756
Previous 8,588 83.47%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
N/A
7,168 Added 83.47%
15,756 $0
Q1 2024

May 10, 2024
BUY
N/A
1,090 Added 14.54%
8,588 $0
Q4 2023

Feb 09, 2024
BUY
N/A
1,562 Added 26.31%
7,498 $0
Q3 2023

Nov 13, 2023
SELL
N/A
-3,574 Reduced 37.58%
5,936 $0
Q2 2023

Aug 15, 2023
BUY
N/A
9,266 Added 3797.54%
9,510 $0
Q1 2023

May 12, 2023
BUY
N/A
8 Added 3.39%
244 $0
Q4 2022

Feb 13, 2023
BUY
$0.0 - $6.07 $0 - $509
84 Added 55.26%
236 $0
Q3 2022

Nov 14, 2022
BUY
$3.91 - $5.52 $15 - $22
4 Added 2.7%
152 $1,000
Q2 2022

Aug 12, 2022
SELL
$2.9 - $4.44 $11,730 - $17,959
-4,045 Reduced 96.47%
148 $1,000
Q1 2022

May 16, 2022
SELL
$3.51 - $6.74 $15,229 - $29,244
-4,339 Reduced 50.86%
4,193 $14,000
Q4 2021

Feb 14, 2022
SELL
$6.03 - $11.67 $50,525 - $97,782
-8,379 Reduced 49.55%
8,532 $57,000
Q3 2021

Nov 15, 2021
BUY
$9.98 - $35.22 $162,903 - $574,896
16,323 Added 2776.02%
16,911 $169,000
Q2 2021

Aug 16, 2021
SELL
$24.71 - $44.28 $93,749 - $167,998
-3,794 Reduced 86.58%
588 $18,000
Q1 2021

May 13, 2021
BUY
$37.62 - $60.41 $164,850 - $264,716
4,382 New
4,382 $191,000

Others Institutions Holding SBTX

# of Institutions
137
Shares Held
62.9M
Call Options Held
1.37M
Put Options Held
83.8K
View Full List

About Silverback Therapeutics, Inc.

SBTX Quotes by TradingView
  • Ticker SBTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,473,800
  • Description
  • Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...
More about SBTX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email